CN Mobile Logo

Search form


Dave Levitan

Dave Levitan

Posts by Author

Chromosomal abnormalities such as a variant t(9;22) translocation do not appear to have significant prognostic impact on children with chronic myeloid leukemia.

Final 10-year follow-up of a large phase III trial showed that adding gemcitabine to anthracycline and taxane-based adjuvant chemotherapy increases toxicity and does not improve disease-free survival in early breast cancer patients.

Molecular subtyping of prostate cancer into three categories—luminal A, luminal B, and basal—identifies differences in prognosis and response to treatment.

Urinary testing for PCA3 and TMPRSS2:ERG (T2:ERG) RNA can help avoid unnecessary biopsies while maintaining ability to detect aggressive prostate cancer.

Treatment with intravesical gemcitabine following surgery reduced the risk of recurrence in patients with low-grade non–muscle invasive bladder cancer.

A prospective phase III validation study found that AZGP1 has significant prognostic utility as a biomarker in localized prostate cancer.

Treatment with metformin may improve outcomes in patients with HER2–positive primary breast cancer and diabetes, according to an analysis of the phase III ALTTO trial.

New studies at the AUA Annual Meeting highlight the links between smoking and bladder cancer. In one, smoking intensity was linked to survival outcomes, while two others show that electronic cigarettes likely contribute to bladder cancer risk.

Two new studies presented at the Annual Scientific Meeting of the American Urological Association offer an improved understanding of some genetic underpinnings of prostate cancer.

Treatment with the gonadotropin-releasing hormone (GnRH) agonist goserelin can reduce the risk of chemotherapy-induced premature ovarian insufficiency (POI) in women with early breast cancer.


By clicking Accept, you agree to become a member of the UBM Medica Community.